AstraZeneca will also share data with regulators from a Phase III study of Tagrisso and Orapthys in lung cancer.

Revolution's RAS inhibitor may be approved in an all-comer population, but molecular profiling remains key to treatment ...

The firm is seeking to expand the indication for its siRNA drug, which is already approved for familial chylomicronemia syndrome.

NEW YORK – Abbisko Therapeutics has begun treating cancer patients harboring KRAS alterations with the pan-KRAS Inhibitor ABSK211 in a Phase I trial.

In search of a molecular diagnosis for a child with bilateral vestibular schwannomas, a family undergoes a diagnostic odyssey ...

Sangrail Biologics is already discussing with the FDA a regulatory path for the gene therapy that Abeona Therapeutics dropped ...

Precision Medicine Group sells clinical research and commercialization services to biopharmaceutical companies, including biomarker-driven R&D.

University of Toronto researchers are betting yes, pointing to tRNA's ease of administration and efficacy advantages over ...

The therapy binds to CD3 receptors on T cells, activating them and directing them past the blood-brain barrier to tumors.

The company said it will use the funds raised from sales of convertible notes to fund its oncology business, including intismeran autogene.

NEW YORK – BioNTech and Roche subsidiary Genentech are discontinuing testing of their jointly developed personalized cancer vaccine in colorectal cancer patients. The companies were testing the mRNA ...

The rise of expensive precision therapies has spawned a growing industry of auxiliary health benefit companies promising to ...